Fascin-1 is a novel biomarker of aggressiveness in some carcinomas by Vathany Kulasingam & Eleftherios P Diamandis
COMMENTARY Open Access
Fascin-1 is a novel biomarker of aggressiveness in
some carcinomas
Vathany Kulasingam1,2 and Eleftherios P Diamandis1,2,3*
Abstract
Tremendous progress has been made in recent years
towards the understanding, prevention and
management of malignant disease, yet cancer remains
a leading cause of global mortality and morbidity.
Current approaches towards combating this disease
include prevention, early detection and various
treatment modalities. However, even with
implementation of novel therapeutic options and
preventative measures, most cancers are currently
diagnosed at late stages, when treatment therapies are
least effective. In a recent study published in BMC
Medicine, Tan et al. performed a systematic review and
meta-analysis to show that fascin-1, an actin-bundling
protein, is associated with increased risk of mortality
and metastasis in various cancer types. Although the
study examined the association of fascin-1 with
mortality, time-to-disease progression, lymph node
metastasis and distant metastasis in five major cancer
types, the clinical implications of these findings are still
unclear and many unanswered questions remain.
Please see related research article here http://www.
biomedcentral.com/1741-7015/11/52
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Background
According to current World Health Organization statis-
tics, cancer accounts for approximately 7.6 million deaths
per annum [1]. Due in part to the expanding and aging of
the world’s population, this number is expected to rise to
a projected 13.1 million deaths per annum in the next
two decades [1]. Because cancer continues to pose a
major threat to human health, it is essential to develop
novel methods for combating it. Current approaches
include prevention, early detection, discovery of new
treatment modalities and combinations of the three, with
a significant portion of research dedicated to develop-
ment of new treatments. Even with novel therapeutic
options and preventative measures in place, the majority
of patients present with locally advanced and/or meta-
static disease at diagnosis [2]. Tumor metastasis remains
a major cause of cancer mortality [3]. A major unmet
need in the field of oncology is the ability of biomarkers
to allow for early characterization of carcinomas accord-
ing to their aggressive potential.
According to data by Tan et al. data published in BMC
Medicine [4], fascin-1 is a novel biomarker for aggressive,
metastatic carcinomas. Fascin-1 is an actin-bundling pro-
tein absent in most normal epithelia but expressed in
many human carcinomas [5]. A number of previous stu-
dies have implicated fascin-1 as a candidate biomarker for
aggressive carcinomas of a large number of cancer types
[5,6]. Immunohistochemical (IHC) studies have shown
that fascin-1 protein expression is correlated with poor
prognosis [6,7]. The objective of Tan et al. was to conduct
a systematic review and meta-analysis of studies that used
IHC to investigate whether fascin-1 could serve as an early
marker for identification of aggressive metastatic potential.
A total of 26 IHC studies examining five cancer types
(breast, colorectal, esophageal, gastric and lung) were
selected after a thorough examination of the literature, fol-
lowing strict inclusion criteria. Outcomes such as mortal-
ity, disease progression, lymph node metastasis and distant
metastasis were examined. The authors approached this
systematic review in a standardized, objective manner by
applying a number of statistical analyses to this study.
Examination of the methodological quality and heteroge-
neity of the studies, as well as various sensitivity analyses,
was carried out.
Clinical implications of fascin-1
The results of the study by Tan et al. revealed that fascin-
1 was associated with an increased risk of mortality for
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breast, colorectal and esophageal cancers. Furthermore,
this protein was associated with an increased risk for dis-
ease progression in breast and colorectal cancers,
whereas an increased risk of both lymph node positivity
and distant metastasis was noted for colorectal and gas-
tric cancers (Table 1). The methodological quality of the
studies did not greatly influence the overall hazard ratio
estimates.
This study raises a number of important questions
regarding fascin-1. First, the pathophysiology of fascin-1
needs to be further elucidated as it is unclear how fascin-
1 could be associated with an increased risk of both
lymph node positivity and distant metastasis in gastric
cancer but have no association with mortality. In addi-
tion, it is unclear how in lung carcinoma the authors
found no association of fascin-1 with lymph node metas-
tasis when figure four in Tan et al. show an increased
risk (relative risk: 1.98; confidence interval: 1.15, 3.41).
With respect to colorectal cancer, it appears that fascin-1
is associated with an increased risk for all four outcomes
examined. These findings suggest that fascin-1 may play
a major role in colorectal cancer development and the
pathophysiology of this needs to be further investigated.
Finally, one of the strengths of this review was that all
included studies used the same two antibodies for the
IHC. It would be interesting to see if the hazard ratio
remains the same if the outcomes from these studies are
examined according to the individual antibody used.
The authors raised an excellent point about the hetero-
geneity within carcinoma types - with the prime example
being breast carcinoma. Here, each of the studies
included different histological types of breast carcinoma.
Further analysis of fascin-1 in subtype-specific breast
cancer is needed. In fact, well-designed prospective stu-
dies are necessary to fully examine the prognostic impact
of fascin-1. Furthermore, a number of previous studies
have shown that fascin-1 is expressed in many cancer
types including cancers of the biliary duct, bladder, brain,
breast, colorectal, kidney, liver, ovary, pancreas and so
forth [6]. This raises the question as to whether this is a
good biomarker, since it is not specific to any tissue type.
Conclusions and perspectives
The findings of this systematic review and meta-analysis by
Tan et al. are clinically relevant and important in the field
of cancer biomarkers. A thorough study was conducted
and the findings raise a number of important questions
regarding the pathophysiology of fascin-1 and how it could
be implemented for routine clinical care in patients diag-
nosed with the major carcinomas examined in this study.
Although prognostic markers are needed, the cornerstone
to combating cancer now and in the future is by early diag-
nosis. Early diagnosis could result in the cure of many
patients with cancer and in more effective treatments for
the rest. As fascin-1 is not a secreted or membrane-bound
protein, it is unlikely that it will serve as a serological bio-
marker for any of the cancer types examined.
Recently, we commented on the failure of many new
cancer biomarkers to reach the clinic [8]. We grouped
the failures into three categories: fraudulent reports,
true discoveries that fail to meet the demands of the
clinic; and false discoveries. Clearly, time will show if
fascin-1 will fall in the second category, or if it will be
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